In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback